explore -WSS

explore

author：focus 2025-09-28 02:31:05 - browse：1

Kevin Sayer, CEO of Dexcom Dexcom

For years, diabetes tech company Dexcom has been striving to get its continuous glucose monitors into the hands of type 2 diabetes patients. Last week at the American Diabetes Association’s conference, the company unveiled plans for software built entirely for these patients, including ones who don’t take insulin.

“We’ve been so focused on things that match the needs of somebody who manages diabetes every minute of every day, and insulin delivery,” Kevin Sayer, CEO of Dexcom, told STAT. “This new product is going to be designed to address the needs of somebody with diabetes who’s not doing that, who has type 2 diabetes and is on other drugs.”

Continuous glucose monitoring is already well-established among people with type 1 diabetes, who rely on constant insulin therapy. The technology, which helps patients noninvasively monitor their blood sugar levels and control their insulin pump in real time, has grown rapidly in use over the years, culminating in a $5 billion market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Faced with fears of OxyContin misuse, sales reps touted its safety

leisure time

WSS

Texas Medical Board asked to define abortion emergency exception

Global cancer cases to surge 77% by 2050, WHO report says

Iran moves toward freeing 5 American citizens who had been imprisoned, in rare deal

Pharma budget tightening trickles down to Doximity

O'Shea Sibley was killed after expressing queer joy by voguing, activists say

Maui funeral service workers on devastation of fires: 'I'm in shock'

hotspot

explore

Wikipedia

Guidelines to prevent youth baseball injuries need more muscle

NYC stabbing: Teen named, arraigned by District Attorney in O'Shae Sibley death

Guidelines to prevent youth baseball injuries need more muscle

Top private equity targets in 2023: cardiology, clinical trials, lasers

23andMe had bad news about my health. I wish a person had delivered it

The CDC's new social media misinformation war

Guidelines to prevent youth baseball injuries need more muscle

Bernie brings in new pharma CEOs to talk drug prices

Dobbs anniversary: the lost opportunity of abortion as health care

Large hospital system sues Multiplan for low

leisure time

Trump, Nauta plead not guilty to new classified docs charges but De Oliveira still not arraigned

A single Democrat is willing to weaken Medicare negotiation power

Presidential candidate assassinated in Ecuador, 1 suspect dead and 6 arrested

Large hospital system sues Multiplan for low

Readout Newsletter: Amgen, Regeneron, BGI Group and more

A protest over insulin prices is seen as a fight for life

explore

Wikipedia

leisure time

explore